Effect of BcL-2 antisense drug with different structure on the biological function of K562 cells
Tóm tắt
Tài liệu tham khảo
Kirkland MA, Obrien SG, Goldman JM. Antisense therapeutics in haematological malignancies[J]. Br J Haematol 1994; 87: 447–52.
Reed JC, Stein C, Subasingle C, et al. Antisense-mediated inhibition of Bcl-2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxy-nucleotides[J]. Cancer Res 1990; 50: 6565–70.
Lei XY, Zhang H. Effect of Bcl-2 antisense oligonucleotide targeting different region of Bcl-2 mRNA on drug-sensitivity of leukemia cells[J]. Chin J Pharmacol Ther 2001; 6: 1–4.
Lei XY, Zhang H, He DM. Bcl-2 antisense oligodeoxynucelotide enhances araninosyl cytosine-induced apoptosis of primary leukemia cells[J]. Chin J Cancer 2002; 21:1301–4.
Wang J, Liu X, Jiang W. Co-transfection of MRP and Bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells[J]. Chin Med J 2000; 113: 957–60.